SEARCH

SEARCH BY CITATION

References

  • Bliss T. V. P. and Collingridge G. L. (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 3139.
  • Blurton-Jones M., Kitazawa M., Martinez-Coria H., Castello N. A., Muller F. J., Loring J. F., Yamasaki T. R., Poon W. W., Green K. N. and Laferla F. M. (2009) Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl Acad. Sci. USA 106, 1359413599.
  • Bomfim T. R., Forny-Germano L., Sathler L. B. et al. (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J. Clin. Invest. 122, 13391353.
  • Bradbury J. (2005) Hope for AD with NGF gene-therapy trial. Lancet Neurol. 4, 335.
  • Carro E. and Torres-Aleman I. (2004) The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. Eur. J. Pharmacol. 490, 127133.
  • Christensen M., Knop F. K., Vilsboll T. and Holst J. J. (2011) Lixisenatide for type 2 diabetis mellitus. Expert Opin. Investig. Drugs 20, 549557.
  • Clarris H. J., Nurcombe V., Small D. H., Beyreuther K. and Masters C. L. (1994) Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants. J. Neurosci. Res. 38, 248258.
  • Covaceuszach S., Capsoni S., Ugolini G., Spirito F., Vignone D. and Cattaneo A. (2009) Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr. Alzheimer Res. 6, 158170.
  • Craft S. (2005) Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 26, 6569.
  • Craft S., Baker L. D., Montine T. J. et al. (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69, 2938.
  • Crisostomo J., Matafome P., Santos-Silva D., Rodrigues L., Sena C. M., Pereira P. and Seica R. (2013) Methylglyoxal chronic administration promotes diabetes-like cardiac ischaemia disease in Wistar normal rats. Nutr. Metab. Cardiovasc. Dis. in press. doi: 10.1016/j.numecd.2013.01.005.
  • Doyle M. E. and Egan J. M. (2007) Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 113, 546593.
  • Drucker D. J. and Nauck M. A. (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 16961705.
  • Duan B., Liu D. S., Huang Y., Zeng W. Z., Wang X., Yu H., Zhu M. X., Chen Z.Y. and Xu T. L. (2012) PI3-kinase/Akt pathway-regulated membrane insertion of acid-sensing ion channel 1a underlies BDNF-induced pain hypersensitivity. J. Neurosci. 32, 63516363.
  • During M. J., Cao L., Zuzga D. S. et al. (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9, 11731179.
  • Engelbrecht B., Stratmann B., Hess C., Tschoepe D. and Gawlowski T. (2013) Impact of GLO1 knock down on GLUT4 trafficking and glucose uptake in L6 myoblasts. PLoS ONE 8, e65195.
  • van Eupen M. G., Schram M. T., Colhoun H. M., Hanssen N. M., Niessen H. W., Tarnow L., Parving H. H., Rossing P., Stehouwer C. D. and Schalkwijk C. G. (2013) The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. Diabetologia 56, 18451855.
  • Fan H., Wang L., Guo F., Wei S. and Zhao R. (2010) Neonatal intramuscular injection of plasmid encoding glucagon-like peptide-1 affects anxiety behaviour and expression of the hippocampal glucocorticoid receptor in adolescent rats. J. Biosci. 35, 6371.
  • Foulstone E. J., Tavare J. M. and Gunn-Moore F. J. (1999) Sustained phosphorylation and activation of protein kinase B correlates with brain-derived neurotrophic factor and insulin stimulated survival of cerebellar granule cells. Neurosci. Lett. 264, 125128.
  • Freiherr J., Hallschmid M., Frey W. H., 2nd, Brunner Y. F., Chapman C. D., Holscher C., Craft S., De Felice F. G. and Benedict C. (2013) Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs 27, 505514.
  • Gilman C. P., Perry T., Furukawa K., Grieg N. H., Egan J. M. and Mattson M. P. (2003) Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J. Neurochem. 87, 11371144.
  • Greig N. H., Mattson M. P., Perry T., Chan S. L., Giordano T., Sambamurti K., Rogers J. T., Ovadia H. and Lahiri D. K. (2004) New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-{alpha} inhibitors, and GLP-1 receptor agonists. Ann. N. Y. Acad. Sci. 1035, 290315.
  • Hamilton A., Patterson S., Porter D., Gault V. A. and Holscher C. (2011) Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 89, 481489.
  • Han W.-N., Holscher C., Yuan L., Yang W., Wang X.-H., Wu M.-N. and Qi J.-S. (2013) Liraglutide protects against ß-amyloid induced impairment of spatial learning and memory in rats. Neurobiol. Aging 32, 576588.
  • Heese K., Low J. W. and Inoue N. (2006) Nerve growth factor, neural stem cells and Alzheimer's disease. Neurosignals 15, 112.
  • Holscher C. (1998) Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol. Dis. 5, 129141.
  • Holscher C. (2011) Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem. Soc. Trans. 39, 891897.
  • Holscher C. (2012) Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection. CNS Drugs 26, 871882.
  • Hoyer S. (1998) Risk factors for Alzheimer's disease during aging. Impacts of glucose/energy metabolism. J. Neural Transm. Suppl. 54, 187194.
  • Hoyer S. (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 490, 115125.
  • Hunter K. and Holscher C. (2012) Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 13, 3338.
  • Jolivalt C. G., Fineman M., Deacon C. F., Carr R. D. and Calcutt N. A. (2011) GLP-1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice. Diabetes Obes. Metab. 13, 9901000.
  • Kaur S., Zilmer K., Leping V. and Zilmer M. (2013) Serum methylglyoxal level and its association with oxidative stress and disease severity in patients with psoriasis. Arch. Dermatol. Res. 305, 489494.
  • Kennedy M. B. (1989) Regulation of neuronal function by calcium. Trends Neurosci. 12, 417420.
  • Kim M., Platt M. J., Shibasaki T., Quaggin S. E., Backx P. H., Seino S., Simpson J. A. and Drucker D. J. (2013) GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat. Med. 19, 567575.
  • Kimura R., Okouchi M., Fujioka H. et al. (2009) Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 162, 12121219.
  • Kordower J. H., Mufson E. J., Fox N., Martel L. and Emerich D. F. (1997) Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates. Exp. Neurol. 145, 586591.
  • Li Y., Tweedie D., Mattson M. P., Holloway H. W. and Greig N. H. (2010) Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem. 113, 16211631.
  • Madsbad S., Krarup T., Deacon C. F. and Holst J. J. (2008) Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr. Opin. Clin. Nutr. Metab. Care 11, 491499.
  • Mattson M. P. (2012) Energy intake and exercise as determinants of brain health and vulnerability to injury and disease. Cell Metab. 16, 706722.
  • McClean P. L., Gault V. A., Harriott P. and Holscher C. (2010) Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. Eur. J. Pharmacol. 630, 158162.
  • McClean P., Parthsarathy V., Faivre E. and Hölscher C. (2011) The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31, 65876594.
  • Moloney A. M., Griffin R. J., Timmons S., O'Connor R., Ravid R. and O'Neill C. (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224243.
  • de la Monte S. M. (2011) Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 72, 4966.
  • Nagahara A. H., Merrill D. A., Coppola G. et al. (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 15, 331337.
  • Nelson T. J. and Alkon D. L. (2005) Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochem. Soc. Trans. 33(Pt 5), 10331036.
  • Noyan-Ashraf M. H., Momen M. A., Ban K., Sadi A. M., Zhou Y. Q., Riazi A. M., Baggio L. L., Henkelman R. M., Husain M. and Drucker D. J. (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58, 975983.
  • Ojo O. O., Abdel-Wahab Y. H., Flatt P. R., Mechkarska M. and Conlon J. M. (2011) Tigerinin-1R: a potent, non-toxic insulin-releasing peptide isolated from the skin of the Asian frog, Hoplobatrachus rugulosus. Diabetes Obes. Metab. 13, 11141122.
  • Parthsarathy V. and Holscher C. (2013a) Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS ONE 8, e58784.
  • Parthsarathy V. and Holscher C. (2013b) The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur. J. Pharmacol. 700, 4250.
  • Perry T. A. and Greig N. H. (2004) A new Alzheimer's disease interventive strategy: GLP-1. Curr. Drug Targets 5, 565571.
  • Perry T. and Greig N. H. (2005) Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2, 377385.
  • Perry T., Lahiri D. K., Chen D., Zhou J., Shaw K. T., Egan J. M. and Greig N. H. (2002) A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300, 958966.
  • Perry T., Lahiri D. K., Sambamurti K., Chen D., Mattson M. P., Egan J. M. and Greig N. H. (2003) Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 72, 603612.
  • Poon W. W., Blurton-Jones M., Tu C. H., Feinberg L. M., Chabrier M. A., Harris J. W., Jeon N. L. and Cotman C. W. (2009) beta-Amyloid impairs axonal BDNF retrograde trafficking. Neurobiol. Aging 39, 821833.
  • Reger M. A., Watson G. S., Green P. S. et al. (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440448.
  • Romani-Perez M., Outeirino-Iglesias V., Gil-Lozano M., Gonzalez-Matias L. C., Mallo F. and Vigo E. (2013) Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats. Endocrinology 154, 11441155.
  • Schulte-Herbruggen O., Braun A., Rochlitzer S., Jockers-Scherubl M. C. and Hellweg R. (2007) Neurotrophic factors–a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases? Curr. Med. Chem. 14, 23182329.
  • Selway J., Rigatti R., Storey N., Lu J., Willars G. B. and Herbert T. P. (2012) Evidence that Ca2+ within the microdomain of the L-type voltage gated Ca2 +  channel activates ERK in MIN6 cells in response to glucagon-like peptide-1. PLoS ONE 7, e33004.
  • Stanton P. K. (1996) LTD., LTP, and the sliding threshold for long-term synaptic plasticity. Hippocampus 6, 3542.
  • Talbot K., Wang H. Y., Kazi H. et al. (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122, 13161338.
  • Vilsboll T. (2009) Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc) 45, 101113.
  • Vlacic-Zischke J., Hamlet S. M., Friis T., Tonetti M. S. and Ivanovski S. (2011) The influence of surface microroughness and hydrophilicity of titanium on the up-regulation of TGFbeta/BMP signalling in osteoblasts. Biomaterials 32, 665671.
  • Wang H.-Y. A., Stucky J., Kvasic S. M., Shah K. P., Bakshi P., McClean C., Holscher C. and Talbot K. (2012) The Diabetes Drug Liraglutide Ameliorates Insulin Resistance in the Hippocampal Formation (HF) of the APP/PS1 Mouse Model of Alzheimer's Disease (AD). Society for Neuroscience Annual Meeting, New Orleans, USA.
  • Zuccato C. and Cattaneo E. (2009) Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5, 311322.